191 related articles for article (PubMed ID: 20039371)
1. Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor.
Tao PL; Law PY; Loh HH
IUBMB Life; 2010 Feb; 62(2):103-11. PubMed ID: 20039371
[TBL] [Abstract][Full Text] [Related]
2. In vivo activation of a mutant mu-opioid receptor by antagonist: future direction for opiate pain treatment paradigm that lacks undesirable side effects.
Yang W; Law PY; Guo X; Loh HH
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2117-21. PubMed ID: 12525693
[TBL] [Abstract][Full Text] [Related]
3. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
4. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
[TBL] [Abstract][Full Text] [Related]
5. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
6. Antinociceptive effects of morphine and naloxone in mu-opioid receptor knockout mice transfected with the MORS196A gene.
Chen SL; Ma HI; Han JM; Lu RB; Tao PL; Law PY; Loh HH
J Biomed Sci; 2010 Apr; 17(1):28. PubMed ID: 20403204
[TBL] [Abstract][Full Text] [Related]
7. In vivo activation of a mutant mu-opioid receptor by naltrexone produces a potent analgesic effect but no tolerance: role of mu-receptor activation and delta-receptor blockade in morphine tolerance.
Roy S; Guo X; Kelschenbach J; Liu Y; Loh HH
J Neurosci; 2005 Mar; 25(12):3229-33. PubMed ID: 15788780
[TBL] [Abstract][Full Text] [Related]
8. MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: a novel dual-acting mu- and kappa-opioid agonist with potent antinociceptive and weak rewarding effects in mice.
Matsumoto K; Takayama H; Narita M; Nakamura A; Suzuki M; Suzuki T; Murayama T; Wongseripipatana S; Misawa K; Kitajima M; Tashima K; Horie S
Neuropharmacology; 2008 Aug; 55(2):154-65. PubMed ID: 18550129
[TBL] [Abstract][Full Text] [Related]
9. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
11. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
[TBL] [Abstract][Full Text] [Related]
14. Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism.
Henderson-Redmond AN; Yuill MB; Lowe TE; Kline AM; Zee ML; Guindon J; Morgan DJ
Brain Res Bull; 2016 May; 123():5-12. PubMed ID: 26521067
[TBL] [Abstract][Full Text] [Related]
15. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of opioids following acute and chronic administration of butorphanol: influence of stimulus intensity and relative efficacy at the mu receptor.
Smith MA; Barrett AC; Picker MJ
Psychopharmacology (Berl); 1999 Apr; 143(3):261-9. PubMed ID: 10353428
[TBL] [Abstract][Full Text] [Related]
18. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.
Wong CS; Cherng CH; Luk HN; Ho ST; Tung CS
Eur J Pharmacol; 1996 Feb; 297(1-2):27-33. PubMed ID: 8851162
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of opioid agonists and antagonists in addiction and pain medicine.
Leri F
Expert Opin Pharmacother; 2008 Jun; 9(8):1387-96. PubMed ID: 18473712
[TBL] [Abstract][Full Text] [Related]
20. A bivalent compound targeting CCR5 and the mu opioid receptor treats inflammatory arthritis pain in mice without inducing pharmacologic tolerance.
Dutta R; Lunzer MM; Auger JL; Akgün E; Portoghese PS; Binstadt BA
Arthritis Res Ther; 2018 Jul; 20(1):154. PubMed ID: 30053832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
